PERCEVAL S Valve Clinical Study for Chinese Registration
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Aortic Valve Disease
- Sponsor
- Corcym S.r.l
- Enrollment
- 61
- Locations
- 1
- Primary Endpoint
- composite endpoint of thromboembolism, all bleeding, all paravalvular leak and endocarditis, structural valve deterioration (SVD) and late all cause death (>30 days)
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a prospective, open, single arm, multi-center clinical study in China. The primary objective of this study is to demonstrate the safety and effectiveness of the PERCEVAL S heart valve when used to replace a diseased native or malfunctioning prosthetic aortic valve in the indicated Chinese population for tissue heart valve replacement and suitable to the PERCEVAL S valve.
The secondary objectives are to collect all relevant device and subject demographics, procedural and hospital discharge, short and long-term data, as described in the secondary endpoints section.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject of age \> 60 years.
- •Subject with aortic valve stenosis or steno-insufficiency.
- •Subject has signed the informed consent.
- •Subject in which preoperative evaluation is indicated for the need of native or prosthetic aortic valve replacement via open heart surgery
- •Subject is located in a geographic location that will enable the subject to return to the study site for follow-up examinations (i.e. geographically stable).
Exclusion Criteria
- •Subject has preexisting valve prosthesis or annuloplasty rings in the mitral, pulmonic or tricuspid position.
- •Subject requires a double or multiple valve replacement or repair of the mitral, tricuspid, or pulmonic valve.
- •Subject requiring simultaneous cardiac procedures, apart from septal myectomy and/or coronary by-pass graft (CABG).
- •Subject has active endocarditis.
- •Subject has active myocarditis
- •Subject has aneurysmal dilation or dissection of the ascending aortic wall.
- •Subject is drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.
- •Subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject.
- •Subject with known hypersensitivity to nickel alloys.
- •Subject is undergoing renal dialysis for chronic renal failure or has hyperparathyroidism.
Outcomes
Primary Outcomes
composite endpoint of thromboembolism, all bleeding, all paravalvular leak and endocarditis, structural valve deterioration (SVD) and late all cause death (>30 days)
Time Frame: at one year
The primary endpoint includes thromboembolism, all bleeding, all paravalvular leak and endocarditis, structural valve deterioration (SVD) and late all cause death (\>30 days) per CEC adjudication The number and percentage of subjects with free from thromboembolism, all bleeding, all paravalvular leak and endocarditis, structural valve deterioration (SVD) and late all cause death will be presented, along with individual component of the success.